• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Viscogliosi Brothers Completes Acquisition of U.S. Spine Business from Stryker, Creating VB Spine, LLC

    4/1/25 4:26:42 PM ET
    $SYK
    Medical/Dental Instruments
    Health Care
    Get the next $SYK alert in real time by email

    VB Spine is a Strategic Partner to Stryker with Access to Mako Spine and Copilot

    Marc, John and Anthony Viscogliosi Lead VB Spine as Co-Chief Executive Officers

    NEW YORK, April 01, 2025 (GLOBE NEWSWIRE) -- Viscogliosi Brothers, LLC, a family-owned investment office specializing in the neuro-musculoskeletal space, today announced the successful completion of its previously announced acquisition of the U.S. spine business from Stryker (NYSE:SYK). The business will operate as a standalone company under the name VB Spine, LLC ("VB Spine").

    VB Spine is advancing toward the completion of its acquisition of Stryker's international spine businesses, pending satisfaction of legal and regulatory requirements, including all required employee consultations. VB Spine is focused on successfully growing and evolving the spine business and expanding its reach to serve surgeons and patients globally.

    VB Spine is dedicated to bringing physicians and patients comprehensive and advanced technology solutions that are clinically proven to deliver improved patient outcomes through surgeon-driven innovation. With a focus on operational excellence and a patient-first approach, VB Spine aims to address critical needs in spine surgery and deliver meaningful improvements in patients' lives. VB Spine's value proposition to all stakeholders lies in its comprehensive product portfolio, strong distribution network and deep industry expertise, enabling it to provide specialized solutions that empower surgeons and enhance patient care. VB Spine is led by Marc, John and Anthony Viscogliosi, co-founders of Viscogliosi Brothers, LLC.

    "We are honored to work alongside such a talented team and are confident that, with its strong commitment to innovation, surgeon collaboration and commercial execution, VB Spine is uniquely positioned to improve patient outcomes and drive transformation in spine surgery," said Marc, John and Anthony Viscogliosi.

    "Viscogliosi Brothers has traditionally been known as a leader in spine technology innovations. With the launch of VB Spine, we are building on our innovation legacy by investing in the people and organization that will drive the next phase of transformation in the spine industry. This transaction represents a major milestone in our dedication to operate a portfolio of innovative and enabling technologies that can improve patient outcomes globally. We look forward to welcoming the rest of the Stryker Spine family as we move forward in our growth strategy through completing the additional phases of the acquisition in markets outside the U.S.," continued Messrs. Viscogliosi.

    VB Spine has access to Stryker's Mako Spine and Copilot. This strategic partnership creates a strong foundation for VB Spine's continued growth, providing surgeons greater precision and improving patient outcomes.

    In connection with the transaction, Barings, LLC and Texas Capital Bank are serving as financial partners to Viscogliosi Brothers. Viscogliosi Brothers and Viscogliosi Brothers Watermark Holdings, LLC are equity investors in VB Spine.

    Viscogliosi Brothers, LLC was advised in this transaction by McDermott Will & Emery as legal counsel, Piper Sandler as financial advisor, FTI Consulting as carve-out advisors and Deloitte IT and Deloitte Tax as additional carve-out advisory.

    About VB Spine

    VB Spine, LLC is the largest privately held spine company and among the largest family-owned medical technology companies in the world. Our globally recognized identity as innovators and stewards of the spine industry reflects our commitment to patient outcomes first. With a comprehensive product portfolio and a large and growing global distribution network, VB Spine delivers specialized solutions that address critical needs in spine surgery and enhance patient outcomes. VB Spine is a strategic partner to Stryker with access to Mako Spine and Copilot. Focused on people, partnerships and operational excellence, VB Spine ensures healthcare professionals have access to the tools and resources needed to provide the highest standard of care. VB Spine is owned and led by the Viscogliosi Brothers. For more information on VB Spine, please visit www.vbspineco.com.

    About Viscogliosi Brothers

    Viscogliosi Brothers, LLC is a family-owned New York City-based family office dedicated to driving growth and innovation in the neuro-musculoskeletal industry. Established in 1999, the firm focuses on identifying and building groundbreaking innovations in healthcare, aiming to address unmet clinical needs, enhance patient outcomes, and drive cost efficiency in the healthcare system. Since its inception 26 years ago, Viscogliosi Brothers has founded, financed, operated and grown 43 businesses with operations and distribution across more than 80 countries. These businesses have positively impacted millions of patients with cutting-edge innovations in healthcare. The firm has led the transformation of the spine industry through its multiple businesses specifically including: Spine Solutions, Spine Next, Paradigm Spine, Simplify Medical, Centinel Spine, Companion Spine, Spine BioPharma and Woven Orthopedic Technologies, among others. For more information, visit www.vbllc.com.

    About Viscogliosi Brothers Watermark

    Viscogliosi Brothers Watermark LLC is a New York City-based holding company specializing in investing in innovation within the MedTech sector. Founded in 2022, VBW is committed to creating alternative wealth for its shareholders while enhancing humanity's well-being. With a portfolio-driven investment mandate and strategic expertise, VBW supports its invested entities through financing and manufacturing capabilities. For more information, visit www.vbwholdings.com.

    About Barings

    Barings is a $421+ billion* global asset management firm that partners with institutional, insurance, and intermediary clients, and supports leading businesses with flexible financing solutions. The firm, a subsidiary of MassMutual, seeks to deliver excess returns by leveraging its global scale and capabilities across public and private markets in fixed income, real assets and capital solutions. For more information, visit www.barings.com

    *Assets under management as of December 31, 2024

    About Texas Capital

    Texas Capital Bancshares, Inc. (NASDAQ®: TCBI), a member of the Russell 2000® Index and the S&P MidCap 400®, is the parent company of Texas Capital Bank ("TCB"). Texas Capital is the collective brand name for TCB and its separate, non-bank affiliates and wholly-owned subsidiaries. Texas Capital is a full-service financial services firm that delivers customized solutions to businesses, entrepreneurs and individual customers. Founded in 1998, the institution is headquartered in Dallas with offices in Austin, Houston, San Antonio and Fort Worth, and has built a network of clients across the country. With the ability to service clients through their entire lifecycles, Texas Capital has established commercial banking, consumer banking, investment banking and wealth management capabilities. All services are subject to applicable laws, regulations, and service terms. Deposit and lending products and services are offered by TCB. For deposit products, member FDIC. For more information, please visit www.texascapital.com.

    About Stryker

    Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.

    Media Contact

    [email protected]



    Primary Logo

    Get the next $SYK alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $SYK

    DatePrice TargetRatingAnalyst
    2/26/2025$450.00Buy
    Citigroup
    12/2/2024$370.00 → $445.00Equal-Weight → Overweight
    Morgan Stanley
    9/10/2024$405.00Outperform
    Wolfe Research
    5/30/2024$372.00Neutral
    Goldman
    5/22/2024$392.00Hold → Buy
    Needham
    1/31/2024$315.00 → $360.00Hold → Buy
    Canaccord Genuity
    10/20/2023$345.00Buy
    ROTH MKM
    9/5/2023$310.00 → $315.00Neutral → Buy
    BofA Securities
    More analyst ratings

    $SYK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citigroup resumed coverage on Stryker with a new price target

      Citigroup resumed coverage of Stryker with a rating of Buy and set a new price target of $450.00

      2/26/25 7:17:53 AM ET
      $SYK
      Medical/Dental Instruments
      Health Care
    • Stryker upgraded by Morgan Stanley with a new price target

      Morgan Stanley upgraded Stryker from Equal-Weight to Overweight and set a new price target of $445.00 from $370.00 previously

      12/2/24 7:02:55 AM ET
      $SYK
      Medical/Dental Instruments
      Health Care
    • Wolfe Research initiated coverage on Stryker with a new price target

      Wolfe Research initiated coverage of Stryker with a rating of Outperform and set a new price target of $405.00

      9/10/24 8:01:33 AM ET
      $SYK
      Medical/Dental Instruments
      Health Care

    $SYK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider King Debra

      3 - STRYKER CORP (0000310764) (Issuer)

      6/4/25 4:42:25 PM ET
      $SYK
      Medical/Dental Instruments
      Health Care
    • Amendment: VP, Chief Accounting Officer Berry William E Jr covered exercise/tax liability with 1,005 shares, decreasing direct ownership by 28% to 2,643 units (SEC Form 4)

      4/A - STRYKER CORP (0000310764) (Issuer)

      5/23/25 7:43:32 PM ET
      $SYK
      Medical/Dental Instruments
      Health Care
    • Amendment: VP, Chief Accounting Officer Berry William E Jr sold $211,370 worth of shares (755 units at $279.96), decreasing direct ownership by 29% to 1,853 units (SEC Form 4)

      4/A - STRYKER CORP (0000310764) (Issuer)

      5/23/25 7:39:38 PM ET
      $SYK
      Medical/Dental Instruments
      Health Care

    $SYK
    Leadership Updates

    Live Leadership Updates

    See more
    • Stryker showcases next generation of Mako SmartRobotics™ at AAOS 2025 Annual Meeting

      Latest technology offers more applications and innovation across more specialties MAHWAH, N.J., March 11, 2025 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, showcases the latest advancements in Mako SmartRobotics™ across hip, knee, spine and shoulder procedures at the American Academy of Orthopaedic Surgeons' (AAOS) 2025 Annual Meeting in San Diego. With over 1.5 million Mako procedures performed globally across 45 countries, Mako is a market-leading technology in orthopaedics. With the introduction of Mako Total Hip with Advanced Primary and Rev

      3/11/25 8:03:00 AM ET
      $SYK
      Medical/Dental Instruments
      Health Care
    • Kadant Set to Join S&P SmallCap 600

      NEW YORK, Feb. 13, 2025 /PRNewswire/ -- Kadant Inc. (NYSE:KAI) will replace Inari Medical Inc. (NASD: NARI) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, February 19. S&P 500 constituent Stryker Corp. (NYSE:SYK) is acquiring Inari Medical in a deal expected to be completed soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name      Action Company Name Ticker GICS Sector February 19, 2025 S&P SmallCap 600 Addition Kadant KAI Industrials February 19, 2025 S&P SmallCap 600 Deletion Inari Medical NARI Health Care For more information about

      2/13/25 5:54:00 PM ET
      $KAI
      $NARI
      $SPGI
      $SYK
      Industrial Machinery/Components
      Industrials
      Medical/Dental Instruments
      Health Care
    • Stryker announces the retirement of Glenn S. Boehnlein and the promotion of Preston Wells to Vice President, Chief Financial Officer

      Portage, Michigan, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced today that Glenn S. Boehnlein will retire from his role as Vice President, Chief Financial Officer. Boehnlein's decision follows an impressive 22-year career at Stryker. Preston Wells, who currently serves as Group CFO for Stryker's Orthopaedics Group, will assume the role of Vice President, Chief Financial Officer effective April 1, 2025. "I want to thank Glenn for his performance drive, strong business partnership, and excellent leadership of the Finance and IT organizations. Glenn is a growth champion who invested in developing talent, including Preston Wells, who has been promoted to Chief Financial Offi

      1/28/25 4:05:00 PM ET
      $SYK
      Medical/Dental Instruments
      Health Care

    $SYK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Stryker Corporation (Amendment)

      SC 13G/A - STRYKER CORP (0000310764) (Subject)

      2/12/24 10:18:54 AM ET
      $SYK
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Stryker Corporation (Amendment)

      SC 13G/A - STRYKER CORP (0000310764) (Subject)

      2/14/23 12:37:55 PM ET
      $SYK
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Stryker Corporation (Amendment)

      SC 13G/A - STRYKER CORP (0000310764) (Subject)

      2/10/23 9:18:16 AM ET
      $SYK
      Medical/Dental Instruments
      Health Care

    $SYK
    SEC Filings

    See more
    • SEC Form S-8 filed by Stryker Corporation

      S-8 - STRYKER CORP (0000310764) (Filer)

      5/30/25 4:16:27 PM ET
      $SYK
      Medical/Dental Instruments
      Health Care
    • SEC Form SD filed by Stryker Corporation

      SD - STRYKER CORP (0000310764) (Filer)

      5/23/25 10:35:54 AM ET
      $SYK
      Medical/Dental Instruments
      Health Care
    • Stryker Corporation filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - STRYKER CORP (0000310764) (Filer)

      5/13/25 5:29:41 PM ET
      $SYK
      Medical/Dental Instruments
      Health Care

    $SYK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Stryker to announce financial results for its second quarter of fiscal year 2025

      Portage, Michigan, July 01, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for its second quarter of fiscal year 2025 on Thursday, July 31, 2025.  A press release will be issued at approximately 4:05 p.m. ET and available at Stryker - Press Releases that day. The press release will include summary financial information for the company's second quarter that ended June 30, 2025. Stryker will host a webcast at 4:30 p.m. ET on Thursday, July 31, 2025, to discuss its second quarter 2025 results.  The webcast can be accessed at Stryker - Events & Presentations.  An archive of the webcast will also be available on the company's website two hours after

      7/1/25 8:00:00 AM ET
      $SYK
      Medical/Dental Instruments
      Health Care
    • Stryker receives FDA clearance for Incompass Total Ankle System

      Streamlining total ankle replacement with data-driven implants and surgical flexibility Stryker (NYSE:SYK), a global leader in medical technologies, announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Incompass® Total Ankle System, an implant intended for patients with ankle joints damaged by severe rheumatoid, post-traumatic, or degenerative arthritis. This new platform integrates the innovative technologies of Stryker's Inbone® and Infinity® systems into a single, comprehensive solution for total ankle replacement. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250625296275/en/Stryker's

      6/25/25 8:15:00 AM ET
      $SYK
      Medical/Dental Instruments
      Health Care
    • Stryker receives FDA clearance for OptaBlate® BVN Basivertebral Nerve Ablation System

      Stryker's first basivertebral nerve ablation system targets the basivertebral nerve to provide relief from chronic* vertebrogenic low back pain. PORTAGE, Mich., May 19, 2025 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, announced that its OptaBlate basivertebral nerve ablation system (OptaBlate BVN) received 510(k) clearance from the U.S. Food and Drug Administration. OptaBlate BVNA is used in a targeted minimally invasive procedure providing long-lasting† vertebrogenic pain relief1. The addition of the OptaBlate BVN to Stryker's pain portfolio expands its advanced pain therapy solutions for patients and is an intersection of its two core competencies: radiofre

      5/19/25 1:01:00 PM ET
      $SYK
      Medical/Dental Instruments
      Health Care

    $SYK
    Financials

    Live finance-specific insights

    See more
    • Stryker declares an $0.84 per share quarterly dividend

      Portage, Michigan, May 08, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.84 per share payable July 31, 2025, to shareholders of record at the close of business on June 30, 2025, representing an increase of 5.0% versus the prior year and unchanged from the previous quarter.  About Stryker Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150

      5/8/25 8:00:00 AM ET
      $SYK
      Medical/Dental Instruments
      Health Care
    • Stryker reports first quarter 2025 operating results

      Portage, Michigan, May 01, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the first quarter of 2025: First Quarter Results Reported net sales increased 11.9% to $5.9 billionOrganic net sales increased 10.1%Reported operating income margin of 14.3%Adjusted operating income margin(1) increased 100 bps to 22.9%Reported EPS decreased 17.6% to $1.69Adjusted EPS(1) increased 13.6% to $2.84  First Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant Currency Acquisitions / Divestitures OrganicMedSurg and Neurotechnology        13.4        %         (0.8)        %         14.2        %         3.5        %         10.7        %Orthopaedics    

      5/1/25 4:05:00 PM ET
      $SYK
      Medical/Dental Instruments
      Health Care
    • Stryker completes acquisition of Inari Medical, Inc., providing entry into the high-growth peripheral vascular segment

      Portage, Michigan, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK), a global leader in medical technologies, announced today that it has completed the acquisition of Inari Medical, Inc. (NASDAQ:NARI), a company that provides innovative solutions for venous thromboembolism (VTE) clot removal without the use of thrombolytic drugs. The addition of Inari brings an established peripheral vascular position to Stryker in the fast-growing VTE segment. "The acquisition of Inari Medical marks a significant milestone in expanding our interventional endovascular portfolio," said Kevin Lobo, Chair and Chief Executive Officer, Stryker. "We look forward to welcoming the talented Inari team to Stryk

      2/19/25 8:30:00 AM ET
      $NARI
      $SYK
      Medical/Dental Instruments
      Health Care